The company warned that if the executive order goes into effect, Roche’s ability to invest $50 billion in its U.S. R&D and manufacturing sites will be in question.
The new laboratory offers technical support for purification of biotherapeutic molecules and is part of the Ecolab Life Sciences Pharma Center of Excellence.
The company plans to expand its U.S. manufacturing capacity through direct investments in production sites and partnerships with other domestic manufacturers.
